Benitec delays IND filing for HIV/AIDS therapeutic pending resolution of manufacturing result
Benitec Ltd. announced that the Investigational New Drug (IND) filing with the US food & Drug Administration (FDA) for its HIV/AIDS therapeutic will be delayed. The delay is due to one aberrant result in the release tests of the clinical materials, not the drug itself.
Sara M. Cunningham, Chief Executive Officer of Benitec, stated "We are working closely with the manufacturing team to resolve this unanticipated result and will move forward as quickly as possible with the IND filing. Although the result is unrelated to the safety or efficacy of the drug, we will not file the IND until we are certain that all components of the clinical materials are fully and properly characterized and pass our stringent manufacturing criteria."
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
KeyNeurotek AG Strengthens Finance and Clinical Development Management
Millipore Acquires NovAseptic AB: Broadens Offering to Biotech and Pharmaceutical Industry
Evotec and Celgene collaborate in drug discovery for neurogenerative diseases
Evotec and Roche Form Global Alliance to Jointly Discover Novel Drugs

Oral vaccine instead of injections? - Exotic workers help with mRNA vaccination through the stomach
Learning how the brain takes out its trash
Newly discovered plant enzyme could lead to more efficient ethanol production from cellulose

Multifunctional catalyst for poison-resistant hydrogen fuel cells
Biotage acquires ATDBio - Biotage strengthens its position in DNA and RNA Oligonucleotide synthesis and purification
Graffinity and Elan launch fragment-based drug discovery collaboration

Q1 Results: Merck Benefits from Global Diversification in a Challenging Environment - Medium-term structural growth drivers intact
